Yangfeng Wu
Peking Union Medical College
5 Papers
126 Citations
Yangfeng Wu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis.
Sheng Kang,Yangfeng Wu,Xian Li +2 more
TL;DR: It is suggested that conventional statins therapy are efficient and safe to decrease the rate of carotid atherosclerosis progression in a long-term, and aggressive statins may provide superior efficacy for carotids Atherosclerosis regression.
133
Cystatin C-based estimated glomerular filtration rate and risk of stroke in the general population: a prospective cohort study
Jin-lan Liao,Fei Xiao,Liuqing Yang,Yanling Wei,Congying Song,Jing Li,Site Yu,Yue-Feng Lu,Jingwen Zhang,Liang Dai,Wei-Wen Liang,Tao Li,Zuying Xiong,Yangfeng Wu,Meg Jardine,Juan Jesus Carrero,Ying Shan,Xiaoyan Huang +17 more
TL;DR: The risks of total stroke and ischemic stroke increased exponentially when the eGFRcys fell below 75 mL/min/1.73 m2, and a U-shaped relationship was witnessed if eGfrcr was used instead, and there was a null association between eG FR and hemorrhagic stroke.
3
Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial.
Xingshan Zhao,Yidan Zhu,Zheng Zhang,Guizhou Tao,Haiyan Xu,Guanchang Cheng,Wen Gao,Liping Ma,Li Qi,Xiao Yan Yan,Haibo Wang,Q. Xia,Yuwang Yang,Q Guo,Wanjun Dang,Chen Yao,Qin Yang,Runlin Gao,Yangfeng Wu,Shubin Qiao +19 more
TL;DR: In this article , a phase II trial on recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA) has previously shown its preliminary efficacy in ST elevation myocardial infarction (STEMI) patients.
Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases.
Vilma E. Irazola,Laura Gutierrez,Gerald S. Bloomfield,Rodrigo M. Carrillo-Larco,Prabhakaran Dorairaj,Thomas A. Gaziano,Naomi S. Levitt,J. Miranda,Antonio Bernabe Ortiz,Krisela Steyn,Yangfeng Wu,Denis Xavier,Lijing L. Yan,Jiang He,Adolfo Rubinstein +14 more
TL;DR: The prevalence of hypertension varies widely in different communities and the rates of awareness, treatment, and control also differ in different settings, suggesting a clear need to focus on increasing hypertension awareness and control in LMICs.
In-hospital major bleeding in patients with acute coronary syndrome medically treated with dual anti-platelet therapy: Associated factors and impact on mortality
Yihong Sun,Lin Feng,Xian Li,Zhe Wang,Runlin Gao,Yangfeng Wu +5 more
TL;DR: Wang et al. as discussed by the authors analyzed data from 19,186 patients on DAPT after acute coronary syndrome with no access to revascularization from Clinical Pathway for Acute Coronary Syndrome in China Phase 3 (CPACS-3) cohort, which was conducted from 2011 to 2014.